Wanhong J. Lu

Xi'an, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.

Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.

Journal: Clinical kidney journal

Published: April 01, 2026

Iptacopan in IgA Nephropathy - Final 24-Month Data.

Iptacopan in IgA Nephropathy - Final 24-Month Data.

Journal: The New England journal of medicine

Published: March 30, 2026

Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.

Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.

Journal: Kidney international reports

Published: January 08, 2026

Delayed onset of systemic lupus erythematosus in patients with idiopathic membranous nephropathy.

Delayed onset of systemic lupus erythematosus in patients with idiopathic membranous nephropathy.

Journal: Lupus

Published: December 19, 2025

TET2 aggravates podocyte mitotic catastrophe and renal injury in diabetic nephropathy via m5C-dependent downregulation of Wee1 and activation of CDK1-cyclinB1 signaling.

TET2 aggravates podocyte mitotic catastrophe and renal injury in diabetic nephropathy via m5C-dependent downregulation of Wee1 and activation of CDK1-cyclinB1 signaling.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: December 04, 2025

Leukocyte telomere length mediates the association between SIRI and CKD: insights from NHANES 1999-2002.

Leukocyte telomere length mediates the association between SIRI and CKD: insights from NHANES 1999-2002.

Journal: Renal failure

Published: October 28, 2025

Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy.

Preliminary analysis of short-term real-world outcomes of telitacicept in high-risk IgA nephropathy.

Journal: Frontiers in medicine

Published: September 03, 2025

Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD.

Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD.

Journal: Renal failure

Published: August 13, 2025

Deciphering N-Glycosylation Dynamics of Serum Monoclonal Immunoglobulins in Multiple Myeloma via EThcD-sceHCD-MS/MS.

Deciphering N-Glycosylation Dynamics of Serum Monoclonal Immunoglobulins in Multiple Myeloma via EThcD-sceHCD-MS/MS.

Journal: Journal of proteome research

Published: April 09, 2025

Elevated effluent lactate independently predicts the adverse outcomes of peritoneal dialysis associated peritonitis.

Elevated effluent lactate independently predicts the adverse outcomes of peritoneal dialysis associated peritonitis.

Journal: Scientific reports

Published: December 29, 2024

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.

Journal: American journal of nephrology

Published: October 17, 2024

Efficacy and safety of belimumab in refractory and newly diagnosed active lupus nephritis patients: a real-world observational study.

Efficacy and safety of belimumab in refractory and newly diagnosed active lupus nephritis patients: a real-world observational study.

Journal: Clinical kidney journal

Published: September 16, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026